Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
Regen BioPharma (OTC:RGBP) announced it will present an update on its Orphan Drug application for HemaXellerate at the Emerging Growth Conference on September 24, 2025. HemaXellerate is being developed to treat aplastic anemia and potentially address chemotherapy side effects, targeting a multi-billion dollar market.
The company's CEO Dr. Koos will discuss the application status and take audience questions during the 10-minute presentation starting at 4:25 PM Eastern. HemaXellerate has already received FDA clearance to proceed with Phase I clinical trials.
Regen BioPharma (OTC:RGBP) ha annunciato che fornirà un aggiornamento sulla domanda di Orphan Drug per HemaXellerate durante la Emerging Growth Conference del 24 settembre 2025. HemaXellerate è in sviluppo per trattare l’anemia aplastica e potrebbe anche mitigare gli effetti collaterali della chemioterapia, puntando a un mercato multimiliardario.
Il CEO dell’azienda, il Dr. Koos, discuterà lo stato della domanda e risponderà alle domande del pubblico durante una presentazione di 10 minuti che inizia alle 4:25 PM Eastern. HemaXellerate ha già ricevuto l’autorizzazione FDA per proseguire con gli studi clinici di Phase I.
Regen BioPharma (OTC:RGBP) anunció que presentará una actualización sobre su solicitud de fármaco huérfano para HemaXellerate en la Emerging Growth Conference el 24 de septiembre de 2025. HemaXellerate se está desarrollando para tratar la anemia aplásica y potencialmente abordar los efectos secundarios de la quimioterapia, apuntando a un mercado de varios miles de millones de dólares.
El CEO de la empresa, el Dr. Koos, discutirá el estado de la solicitud y responderá a las preguntas del público durante la presentación de 10 minutos que comenzará a las 4:25 PM, hora del Este. HemaXellerate ya recibió la aprobación de la FDA para continuar con ensayos clínicos de Fase I.
Regen BioPharma (OTC:RGBP)은 헤마쎌러레이트(HemaXellerate) 희귀의약품 신청에 관한 업데이트를 2025년 9월 24일 열리는 Emerging Growth Conference에서 발표할 예정이라고 발표했다. HemaXellerate는 재생불량성 빈혈 치료를 목표로 개발 중이며, 화학요법의 부작용을 해결할 수 있어 수십억 달러 규모의 시장을 겨냥한다.
회사의 CEO인 Dr. Koos가 신청 현황을 논의하고 10분 발표 중 청중의 질문에 답할 것이다. 발표는 동부 표준시 기준 오후 4:25에 시작된다. HemaXellerate는 이미 FDA 승인을 받아 1상 임상시험을 진행할 수 있다.
Regen BioPharma (OTC:RGBP) a annoncé qu'il présentera une mise à jour sur sa demande de médicament orphelin pour HemaXellerate lors de la Emerging Growth Conference le 24 septembre 2025. HemaXellerate est en cours de développement pour traiter l’anémie aplasique et pourrait également atténuer les effets secondaires de la chimiothérapie, ciblant un marché de plusieurs milliards.
Le PDG de l'entreprise, le Dr Koos, discutera de l'état de la demande et répondra aux questions du public lors d'une présentation de 10 minutes qui commencera à 16h25, heure de l'Est. HemaXellerate a déjà reçu l'autorisation de la FDA pour démarrer les essais cliniques de phase I.
Regen BioPharma (OTC:RGBP) kündigte an, dass es am 24. September 2025 ein Update zu seinem Orphan-Drug-Antrag für HemaXellerate bei der Emerging Growth Conference geben wird. HemaXellerate wird entwickelt, um aplastische Anämie zu behandeln und möglicherweise Nebenwirkungen der Chemotherapie anzugehen, mit einem Zielmarkt von mehreren Milliarden Dollar.
Der Geschäftsführer Dr. Koos wird den Antragsstatus erörtern und während der 10-minütigen Präsentation Fragen des Publikums beantworten. Die Präsentation beginnt um 16:25 Uhr Ostküstenzeit. HemaXellerate hat bereits die FDA-Zulassung erhalten, um mit Phase-I-Studien fortzufahren.
Regen BioPharma (OTC:RGBP) أعلنت أنها ستقدّم تحديثاً بشأن طلب دواء فريد للمؤسسة ( orphan drug) لـ HemaXellerate خلال مؤتمر Emerging Growth في 24 سبتمبر 2025. يتم تطوير HemaXellerate لعلاج فقر الدم اللانخاعي وربما معالجة آثار العلاج الكيميائي، مستهدفاً سوقاً يقدر بمليارات الدولارات.
سيناقش الرئيس التنفيذي للشركة الدكتور كوس وضع الطلب وسيجيب على أسئلة الجمهور خلال عرض مدته 10 دقائق يبدأ في الساعة 4:25 مساءً بتوقيت الساحل الشرقي. وقد حصلت HemaXellerate بالفعل على موافقة FDA للمضي قدماً في التجارب السريرية للمرحلة الأولى.
Regen BioPharma（OTC:RGBP）宣布将于2025年9月24日在新兴增长大会上就其< b>HemaXellerate的孤儿药申请提供更新。HemaXellerate正在开发用于治疗再生障碍性贫血，并可能缓解化疗副作用，瞄准一个数十亿美元级的市场。
该公司CEO Koos博士将讨论申请状态，并在为期10分钟的演示中回答听众提问，演示将于美国东部时间16:25开始。HemaXellerate已经获得FDA批准进入I期临床试验。
- None.
- None.
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company will be presenting an update on its application for Orphan Drug status to the U.S. Food and Drug Administration (FDA) for HemaXellerate. This therapy is anticipated being used in treating aplastic anemia. Additionally the Company anticipates HemaXellerate may be used in addressing the side effects of Chemotherapy, a market of several billions of dollars.
The Company’s Chairman and CEO, Dr. Koos said he will be making the update on the Orphan Drug Application and answering questions from the audience. The Company has stated it is poised to move into Clinical Phase I with HemaXellerate, which has already been cleared by the FDA.
If you would like to participate in the conference or ask questions, please use the link: https://goto.webcasts.com/starthere.jsp?ei=1717091&tp_key=c78a55764a&sti=rgbp to register. The conference presentation will start at 4:25 pm Eastern on September 24th and last for approximately 10 minutes
About Regen BioPharma, Inc.
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Email: david.koos@regenbiopharmainc.com or
david.koos@regenbiopharmainc.com
X (formerly twitter): https://x.com/TheRegenBio
FAQ
When is Regen BioPharma (RGBP) presenting at the Emerging Growth Conference?
What is HemaXellerate being developed for by Regen BioPharma (RGBP)?
What is the current status of Regen BioPharma's (RGBP) HemaXellerate development?
How can investors participate in Regen BioPharma's (RGBP) conference presentation?
